Consequently, using zebrafish PDX model we demonstrate that targeting of the CD44 + populations in vivo results in significantly abrogated growth of tumour bulk supporting the efficacy of therapeutic strategies targeting TICs in glioma. This evidence concerns the gene CD44 and central nervous system cancer.